Tumor necrosis factor alpha-induced vascular cell adhesion molecule 1 expression (TNFα/VCAM-1)

TNFα-related signaling and VCAM-1 expression refers to the pro-inflammatory signaling axis where Tumor Necrosis Factor alpha (TNFα) induces the expression of Vascular Cell Adhesion Molecule 1 (VCAM-1) (Source: PubMed, PMID: 10409140). This process is a central component of endothelial activation and is primarily mediated by the NF-κB signaling pathway (Source: PubMed, PMID: 11592333). When TNFα binds to its receptors, TNFR1 or TNFR2, it initiates a cascade that leads to the phosphorylation and degradation of IκB, allowing NF-κB to translocate to the nucleus (Source: UniProt, P01375). Once in the nucleus, NF-κB binds to specific promoter elements of the VCAM1 gene to stimulate its transcription (Source: UniProt, P19320). The resulting VCAM-1 protein is expressed on the cell surface, where it mediates the adhesion and recruitment of leukocytes to sites of inflammation (Source: PubMed, PMID: 17604408). This axis plays a critical role in the development of atherosclerosis and various autoimmune conditions, such as rheumatoid arthritis and inflammatory bowel disease (Source: StatPearls, "TNF Inhibitors"). Therapeutic strategies targeting this pathway predominantly involve TNFα antagonists, which block the cytokine from interacting with its receptors (Source: NIH, "Tumor Necrosis Factor-alpha Inhibitors"). By inhibiting this signaling, these drugs effectively reduce VCAM-1 expression and subsequent tissue inflammation, though they carry risks of serious infections and malignancy (Source: FDA, "Enbrel Label").

Other names

TNF-alpha/VCAM-1 axisTNF-induced endothelial activationTNF-alpha signaling pathwayVCAM-1 induction pathway

Inhibition of TNFα binding to its receptors (TNFR1/TNFR2), thereby preventing the downstream NF-κB-mediated transcriptional upregulation of VCAM-1.